Ngm Biopharmaceuticals (NASDAQ: NGM)
Some price data may be temporarily unavailable.
Ngm Biopharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ngm Biopharmaceuticals Company Info
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
News & Analysis
Is Good News Enough for You to Buy NGM on the Dip?
A drop in the overall market provides an opportunity for investors to pounce.
Why NGM Biopharmaceuticals Dived by 41% on Monday
The results of a hepatitis drug candidate's clinical trial were not good.
NGM Biopharmaceuticals Reports a Successful NASH Trial
Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.
Here's Why NGM Biopharmaceuticals Is Soaring Today
Shares popped after the clinical-stage biotech reported upbeat clinical results.
Why Aurora Cannabis, Sorrento Therapeutics, and NGM Biopharmaceuticals Slumped Today
Tough industry conditions and company-specific issues hit these stocks.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.